Short Interest in Theratechnologies Inc. (NASDAQ:THTX) Rises By 226.0%

Theratechnologies Inc. (NASDAQ:THTX) saw a large growth in short interest in October. As of October 15th, there was short interest totalling 33,900 shares, a growth of 226.0% from the September 30th total of 10,400 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 33,400 shares, the short-interest ratio is currently 1.0 days.

Hedge Funds Weigh In On Theratechnologies

A hedge fund recently raised its stake in Theratechnologies stock. Cyndeo Wealth Partners LLC lifted its stake in shares of Theratechnologies Inc. (NASDAQ:THTX) by 26.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 131,311 shares of the company’s stock after purchasing an additional 27,191 shares during the period. Cyndeo Wealth Partners LLC owned 0.29% of Theratechnologies worth $163,000 at the end of the most recent quarter.

Theratechnologies Stock Down 1.6 %

NASDAQ THTX traded down $0.02 during trading on Friday, hitting $1.23. The company’s stock had a trading volume of 33,639 shares, compared to its average volume of 45,257. Theratechnologies has a 52 week low of $0.88 and a 52 week high of $2.58. The firm has a 50 day moving average price of $1.26 and a 200 day moving average price of $1.32. The firm has a market cap of $56.56 million, a P/E ratio of -6.47 and a beta of 1.41.

Theratechnologies (NASDAQ:THTX) last posted its earnings results on Thursday, October 10th. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $22.60 million during the quarter. During the same period last year, the firm posted ($0.03) earnings per share. On average, equities analysts expect that Theratechnologies will post 0.03 earnings per share for the current year.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.